Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Brazil Up to 0.3% THC in plants authorised for medical, pharmaceutical, industrial use ...
  • Australia Parliamentary committee makes suggestions for cannabis law in NSW ...
  • Australia Greens announce Parliament will vote on cannabis legalisation this month ...
  • Texas - United States Bills introduced in Senate and House on medical cannabis expansion ...
  • Texas - United States House bill introduced to regulate hemp production and require research permit ...
  • Texas - United States House bills introduced on legalising recreational cannabis ...
  • Lithuania - Ukraine Cannabis conference focuses on fibre hemp, addressing challenges, restrictions ...
  • Czech Republic Criminal law reform approved, will relax some cannabis-related laws ...
  • New Zealand First sublingual THC/CBD spray meets Medicinal Cannabis Agency quality standard ...
  • Poland Motion for cannabis decriminalisation presented to prime minister ...
  • Belgium Health Belgium updates notified herbal products for smoking list ...
  • Portugal Infarmed withdraws several CBD products from market ...
View all
News analysis

More of the same in US 2022 – expect state moves and federal stalemate

Written by || 17th January 2022 || News analysis | Policy and Politics | Regulation and legislation | US federal regulation | GeographiesNorth America United States

Last year saw no movement on cannabinoid issues at federal level in the US, as CBD-Intel predicted, and it’s not looking too good for this year either – though some continued movement at state level on medical and recreational cannabis is expected at the least.

Overall our outlook on the regulation of cannabis in the US in 2021 provided more hits than misses. We correctly predicted that the Food and Drug Administration (FDA) would not make a legal pathway for CBD products in 2021 but we were slightly over-optimistic that Congress would pass some sort of federal cannabis reform.

Read full article

Download the full news analysis

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber

Login

Anthony Traurig

Head legal analyst
Anthony focuses on regulatory developments and legal analysis in the US. Anthony has a BA in political science from North Carolina State University and a JD from Charleston School of Law (South Carolina), where he was a senior editor on the law review. He practised law for several years in the United States as a litigator.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.